View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+3)
  • Guy Sips
  • Michiel Declercq
  • Wim Lewi
Guy Sips
  • Guy Sips

DEME They Came, Dredged/Drilled, Delivered — Standing Still Isn't in t...

DEME is a world leader in the specialised fields of dredging, marine infrastructure, solutions for the offshore energy market, and environmental works. DEME can build on exactly 150 years of know-how and experience and has fostered a pioneering approach throughout its history, being a front runner in innovation and new technologies. We raise our Target Price —from € 230 to € 240, in line with our DCF—after updating our model to reflect higher FY26E and outer-year EBITDA margins. Recall that FY25...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin
Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin
Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update March 2026: Removing Aedifica – Adding Pr...

The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continue into 2027. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. The highly anticipated AI productivity gains also will have to transpire sooner or later or a US market correction becomes unavoidable. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We...

 PRESS RELEASE

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

 PRESS RELEASE

Inventiva participera à quatre conférences investisseurs en mars

Inventiva participera à quatre conférences investisseurs en mars  Daix (France), New York (États-Unis), le 26 février 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que la direction de la Société participera à des réunions individuelles et à des présentations lors des événements investisseurs suivants : TD Cowen 46ème Health Care Conference – 2 au 4 mars 2026Date : lun...

 PRESS RELEASE

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...

 PRESS RELEASE

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi

Morning Notes : ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, ...

: ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, UCB BB, SHUR BB, CTPNV NA, DEME BB, SYENS BB

Guy Sips
  • Guy Sips

DEME Top-line in line, EBITDA-margin 22.4% vs our 20.8% (CSS 21.0%)

DEME posted a very solid FY25 with turnover of €4.2bn, broadly in line with expectations, supported by 4% y/y growth in Offshore Energy. Dredging & Infra maintained its record FY24 level at just under €2bn, while Environmental declined 19% y/y to €272m. The order book increased to €7.6bn, benefitting from new awards and the integration of Havfram. FY25 EBITDA rose 22% y/y to a very nice €9 30.5m (KBCSe €871.6m), lifting the margin to 22.4% on strong Offshore Energy performance. Dredging & In...

 PRESS RELEASE

Full-year results 2025: record performance marks 150 years of deliver...

Full-year results 2025: record performance marks 150 years of delivery Highlights  Record results with Group turnover at 4.2 billion euros compared to 4.1 billion euros a year agoEBITDA at 931 million euros from 764 million euros a year ago, an increase of 22%, and reaching 22.4% of turnover, up from 18.6% for 2024Net profit reaching 346 million euros, compared to 288 million euros a year ago, an increase of 20%Proposed gross dividend of 4.5 euros per share, compared to 3.8 euros per share a year ago Order book stood at 7.6 billion euros at the end of the year, above both mid-year and...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch